Atlas Trials

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT07601607 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07601607
Sponsor
Sun Yat-sen University
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Start date
2026-05-30
Primary completion
2028-05-30
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.